DeutschNewstral
Article
bizjournals.com on 2016-05-20 20:34
Reata Pharmaceuticals sets terms for initial public offering
Related news
- MZentalis Pharmaceuticals sets IPO terms, to be valued at up to $592 millionmarketwatch.com
- MSatsuma Pharmaceuticals sets IPO terms to raise up to $80 millionmarketwatch.com
- MDova Pharmaceuticals sets IPO terms to raise $69.1 million before optionsmarketwatch.com
- Reata Pharmaceuticals surges more than 23 percent in stock debutbizjournals.com
Plano’s Reata Pharmaceuticals halts chronic kidney disease drug developmentDallas News- MInstacart sets terms in initial public offering with proposed market cap of $7.5B2 min readmarketwatch.com
- Plano’s Reata Pharmaceuticals strikes a $7.3 billion deal with biotech giant BiogenDallas News
- MSyros Pharmaceuticals sets IPO price expectationsmarketwatch.com
- MBiogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering2 min readmarketwatch.com
Levi Strauss Files for Initial Public Offeringwsj.com
How To Assess An Initial Coin OfferingInc.- Chobani Files for Initial Public Offeringwsj.com
- VRegulators approve Station Casinos initial public offeringvegasinc.com
- AppDynamics Sets Terms for IPOwsj.com
- MAtlassian Corp. sets initial public offering rangemarketwatch.com
- MNutanix's valuation drops after initial IPO pricing terms setmarketwatch.com
- MStocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts’ over future operations2 min readmarketwatch.com
Etsy files for U.S. initial public offering of craft websiteThe Globe and Mail
CrowdStrike sets terms for $378M Nasdaq IPOTechCrunch- IPanera Bread files for an initial public offering (IPO)invezz.com